Compass Therapeutics, Inc. (NASDAQ: CMPX) had its price target raised by analysts at HC Wainwright from $10.00 to $24.00. They now have a "buy" rating on the stock.
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $12.00 price target on the stock.
Compass Therapeutics And 2 More Compelling Penny Stocks [Yahoo! Finance]